<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00240097</url>
  </required_header>
  <id_info>
    <org_study_id>F041222002</org_study_id>
    <secondary_id>UAB 0421</secondary_id>
    <nct_id>NCT00240097</nct_id>
  </id_info>
  <brief_title>Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)</brief_title>
  <official_title>Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin-Etoposide/Carboplatin in Extensive SCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi-Synthelabo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of Part I of the study is to determine tumor response rate of
      sequential topoisomerase targeting with irinotecan/oxaliplatin followed by etoposide
      /carboplatin in chemotherapy-naïve patients with extensive small cell lung cancer. The
      primary objective of Part II of the study is to determine the objective tumor response rate
      of irinotecan/oxaliplatin in patients with either refractory disease or who have relapsed to
      first line chemotherapy or chemoradiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, open label study for either chemotherapy-naïve patients with extensive
      SCLC or patients who are refractory or have relapsed to 1st line therapy for SCLC. The
      primary objective is to determine the objective response rate.

      This study consists of 2 parts:

      Part I - Chemotherapy-naïve patients with extensive SCLC

      • These patients will be treated with sequential topoisomerase targeting regimens (Regimen A
      and B). Regimen A consists of irinotecan and oxaliplatin (IROX), given on Day 1, and Neulasta
      administered on Day 2. Regimen B consists of etoposide and carboplatin, given on Day
      15(etoposide will be given daily x 3)and Neulasta on Day 18. Then, Regimen A will be given
      again 3 weeks later. The first re-evaluation for response will be performed 3 weeks after the
      second round of the sequential regimens.

      Schema of Part I:

      Regimen A (→ 2 weeks) Regimen B (→ 3 weeks) Regimen A (→ 2 weeks) Regimen B → (3 weeks) →
      Re-Stage

        -  The second re-evaluation for response will be performed 3 weeks after the fourth round
           of the sequential regimen. At this point patients with stable disease will be observed;
           those with either a partial or complete response will be treated with another round of
           sequential therapy (Regimen A → Regimen B) if there is no evidence of unacceptable
           toxicity. At the end (3 weeks after) of the fifth round of chemotherapy, patients will
           be re-evaluated for response, and will be followed-up for recurrent disease every 8
           weeks.

        -  Analysis of Top I and Top II levels in peripheral blood mononuclear cells will be
           performed in 10 patients of Part I.

        -  Evaluation of the expression of the ERCC genes (ERCC1, ERCC2, and XPF) will be performed
           in those patients in Part I with an adequate tumor specimen.

      Part II - Patients who have either refractory disease or have relapsed from 1st line therapy

      • These patients will be treated with Regimen A1 (IROX) at 3-week intervals. Neulasta will be
      administered on Day 2 of each cycle. The first re-evaluation for response will be performed 3
      weeks after the 3rd cycle of Regimen A1. The second re-evaluation for response will be
      performed 3 weeks after the 6th cycle of Regimen A1. At this point, patients with stable
      disease will be observed; those with either a partial or complete response will be treated
      with two additional cycles of Regimen A1 if there is no evidence of unacceptable toxicity. At
      the end (3 weeks after) of the 8th cycle of Regimen A1, patients will be re-evaluated for
      response, and will be followed-up for recurrent disease every 8 weeks.

      Schema of Part II:

      Regimen A1 (→ 3 weeks) Regimen A1 (→ 3 weeks) Regimen A1 (→ 3 weeks) Re-Stage
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (Part I)</measure>
    <time_frame>baseline to 18 months</time_frame>
    <description>The primary objective is to determine the objective tumor response rate of sequential topoisomerase targeting with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy-naïve patients with extensive SCLC and Stage IIIb (wet) - IV Large Cell Carcinoma of the Lung with neuroendocrine markers. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Stable response means did not meet criteria for progressive or partical response. 20% progressive disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate After Relapse</measure>
    <time_frame>3 weeks after 3rd cycle of starting therapy after relapse or refractory disease</time_frame>
    <description>The objective is to determine the objective tumor response rate of sequential topoisomerase targeting with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy-naïve patients with extensive SCLC and Stage IIIb (wet) - IV Large Cell Carcinoma of the Lung with neuroendocrine markers. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Stable response means did not meet criteria for progressive or partical response. 20% progressive disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (Part I)</measure>
    <time_frame>baseline to five years</time_frame>
    <description>Time to progressive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (Part I)</measure>
    <time_frame>baseline to 2 years</time_frame>
    <description>Length of subject survival after starting study treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Irinotecan; Oxaliplatin; Neulasta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etoposide; Carboplatin; Neulasta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) area under the concentration curve (AUC) 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intervention A: Irinotecan; Oxaliplatin; Neulasta</intervention_name>
    <description>Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)</description>
    <arm_group_label>Irinotecan; Oxaliplatin; Neulasta</arm_group_label>
    <other_name>Camptosar</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>Pegfilgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intervention B: Etoposide; Carboplatin; Neulasta</intervention_name>
    <description>Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) AUC 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)</description>
    <arm_group_label>Etoposide; Carboplatin; Neulasta</arm_group_label>
    <other_name>VP-16</other_name>
    <other_name>Etopophos®</other_name>
    <other_name>Vepesid®</other_name>
    <other_name>Taxol</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Pegfilgrastim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologic or cytologic diagnosis of SCLC.

          2. Measurable or assessable tumor parameters.

          3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.

          4. Age between 18 and 79 years (in the State of Alabama &gt; 18).

          5. Adequate bone marrow, liver and renal function, defined as:

               -  Absolute neutrophil count (ANC) ≥ 1500/µL

               -  Platelet count ≥ 100,000/µL

               -  SGOT/SGPT ≤ 2.5 x upper limit of normal or ≤ 5 x upper limit of normal when liver
                  metastases are present.

               -  Total bilirubin value ≤ 1.5 x upper limit of normal.

               -  Serum creatinine value ≤ 1.5 x upper limit of normal.

          6. Fully recovered from any previous surgery (at least 4 weeks since major surgery)

          7. Must have recovered from prior radiation therapy (at least 3 weeks)

          8. All participants must agree to practice approved methods of birth control (if
             applicable). A negative pregnancy test must be documented during the screening period
             for women of childbearing potential.

          9. Must provide written informed consent and authorization to use and disclose health
             information (HIPAA).

             For Part I

         10. Extensive-stage SCLC as defined as disease not confined to one hemithorax, including
             ipsilateral pleural effusion or pericardial effusion.

         11. No prior chemotherapy.

             For Part II

         12. Patients with either refractory disease, or who have relapsed 1st line therapy. No
             prior chemotherapy with Oxaliplatin or irinotecan.

         13. Demonstrated tumor progression at the time of study entry.

        Exclusion Criteria:

          1. Concurrent cancer chemotherapy, biologic therapy or radiotherapy.

          2. Administration of any investigational drug within 28 days prior to administration of
             the current therapy.

          3. Symptomatic brain metastases; those patients should be treated first with either whole
             brain radiation therapy or radiosurgery.

          4. Concurrent serious infection.

          5. Concomitant severe or uncontrolled underlying medical disease unrelated to the tumor,
             which is likely to compromise patient safety and affect the outcome of the study.

          6. History of other malignancy (except non-melanoma skin cancer or carcinoma in situ of
             the cervix), unless in complete remission and off all therapy for a minimum of 2
             years.

          7. Neuropathy at baseline ≥ Grade 2.

          8. Any evidence or history of hypersensitivity or other contraindications for the drugs
             used in this trial.

          9. History of chronic diarrhea; or diarrhea (excess of 2-3 stools/day above normal
             frequency) in the past 2 weeks.

         10. History of a positive serology for human immunodeficiency virus (HIV).

         11. Psychiatric disorder that prevents patients from providing informed consent or
             following protocol instructions.

         12. Pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Robert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2005</study_first_submitted>
  <study_first_submitted_qc>October 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2005</study_first_posted>
  <results_first_submitted>June 8, 2012</results_first_submitted>
  <results_first_submitted_qc>November 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 27, 2014</results_first_posted>
  <last_update_submitted>November 26, 2014</last_update_submitted>
  <last_update_submitted_qc>November 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Francisco Robert,MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Regimen A and B</title>
          <description>Regimen A Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
Regimen B Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) AUC 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>histology</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unevaluable</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>did not continue from Part I</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Regimen A and B</title>
          <description>Chemotherapy-naive patients with extensive SCLC will be treated in one of two regimens: Regimen A consists of treatment with irinotecan and oxaliplatin given every 2 weeks while Regimen B consists of etoposide and carboplatin given every 3 weeks. Both regimens will include re-evaluation for response at least every 8 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (Part I)</title>
        <description>Time to progressive disease</description>
        <time_frame>baseline to five years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Regimen A and B</title>
            <description>Chemotherapy-naive patients with extensive SCLC will be treated in one of two regimens: Regimen A consists of treatment with irinotecan and oxaliplatin given every 2 weeks while Regimen B consists of etoposide and carboplatin given every 3 weeks. Both regimens will include re-evaluation for response at least every 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (Part I)</title>
          <description>Time to progressive disease</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.95" lower_limit="6.5" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (Part I)</title>
        <description>The primary objective is to determine the objective tumor response rate of sequential topoisomerase targeting with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy-naïve patients with extensive SCLC and Stage IIIb (wet) – IV Large Cell Carcinoma of the Lung with neuroendocrine markers. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Stable response means did not meet criteria for progressive or partical response. 20% progressive disease.</description>
        <time_frame>baseline to 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Regimen A and B</title>
            <description>Chemotherapy-naive patients with extensive SCLC will be treated in one of two regimens: Regimen A consists of treatment with irinotecan and oxaliplatin given every 2 weeks while Regimen B consists of etoposide and carboplatin given every 3 weeks. Both regimens will include re-evaluation for response at least every 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (Part I)</title>
          <description>The primary objective is to determine the objective tumor response rate of sequential topoisomerase targeting with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy-naïve patients with extensive SCLC and Stage IIIb (wet) – IV Large Cell Carcinoma of the Lung with neuroendocrine markers. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Stable response means did not meet criteria for progressive or partical response. 20% progressive disease.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unevaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (Part I)</title>
        <description>Length of subject survival after starting study treatment</description>
        <time_frame>baseline to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Regimen A and B</title>
            <description>Chemotherapy-naive patients with extensive SCLC will be treated in one of two regimens: Regimen A consists of treatment with irinotecan and oxaliplatin given every 2 weeks while Regimen B consists of etoposide and carboplatin given every 3 weeks. Both regimens will include re-evaluation for response at least every 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (Part I)</title>
          <description>Length of subject survival after starting study treatment</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="10.2" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Response Rate After Relapse</title>
        <description>The objective is to determine the objective tumor response rate of sequential topoisomerase targeting with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy-naïve patients with extensive SCLC and Stage IIIb (wet) – IV Large Cell Carcinoma of the Lung with neuroendocrine markers. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Stable response means did not meet criteria for progressive or partical response. 20% progressive disease.</description>
        <time_frame>3 weeks after 3rd cycle of starting therapy after relapse or refractory disease</time_frame>
        <population>All subjects dropped out or died prior to experiencing relapse</population>
        <group_list>
          <group group_id="O1">
            <title>Part II - After Relapse</title>
            <description>Study dosing with A and B based on relapse</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate After Relapse</title>
          <description>The objective is to determine the objective tumor response rate of sequential topoisomerase targeting with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy-naïve patients with extensive SCLC and Stage IIIb (wet) – IV Large Cell Carcinoma of the Lung with neuroendocrine markers. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Stable response means did not meet criteria for progressive or partical response. 20% progressive disease.</description>
          <population>All subjects dropped out or died prior to experiencing relapse</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Regimen A First Cycle</title>
          <description>Regimen A Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)</description>
        </group>
        <group group_id="E2">
          <title>Regimen B First Cycle</title>
          <description>Regimen B Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) AUC 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)</description>
        </group>
        <group group_id="E3">
          <title>Regimen A Overall Toxicity</title>
          <description>Regimen A Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)</description>
        </group>
        <group group_id="E4">
          <title>Regimen B Overall Toxicity</title>
          <description>Regimen B Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) AUC 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCT CTAE</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Thrombocytopenia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" events="24" subjects_affected="19" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Grade 4 Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" events="22" subjects_affected="15" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Grade 3 Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Grade 3 Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Grade 4 Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 nausea and vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Grade 3 diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Grade 3 Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>NCI CTAE</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea and vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="16" subjects_affected="12" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E3" events="29" subjects_affected="20" subjects_at_risk="26"/>
                <counts group_id="E4" events="22" subjects_affected="13" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Francisco Robert</name_or_title>
      <organization>UAB</organization>
      <phone>205-934-5077</phone>
      <email>pacorobertuab@cs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

